IP Library › Granted Patent US 12,221,493
Granted Patent B2
US 12,221,493 · App. 17/238,806 · Granted Feb 11, 2025

Immunotherapy against several tumors including neuronal and brain tumors

Inventors: Toni Weinschenk (Aichwald, DE); Oliver Schoor (Tuebingen, DE); Claudia Trautwein (Wuelfrath, DE); Norbert Hilf (Kirchentellinsfurt, DE); Steffen Walter (Houston, TX); Harpreet Singh (Munich, DE)
Assignee: Immatics Biotechnologies GmbH
C07K7/06A61K35/17A61K39/00A61K39/0011A61K39/4611A61K39/4644A61M5/002C07K7/08C07K14/70539C12N5/0638C12N5/0639G01N33/57492A61K38/00A61K2039/53A61K2039/55511A61K2039/55516A61K2039/55522A61K2039/55561A61K2039/55588A61K2039/572A61K2039/605A61K2039/6081A61K2039/6093C07K7/00C07K2319/00C07K2319/40C12N2501/50Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,221,493
App. No.
17/238,806
Granted
Feb 11, 2025
Kind
B2
Abstract

The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.

Claims (17)

1. An isolated peptide consisting of the amino acid sequence ALWAWPSEL (SEQ ID NO: 5) in the form of a pharmaceutically acceptable salt, wherein said peptide is produced by solid phase peptide synthesis or produced by a yeast cell or bacterial cell expression system.

2. The peptide of claim 1 , wherein the pharmaceutically acceptable salt is chloride salt.

3. The peptide of claim 1 , wherein the pharmaceutically acceptable salt is acetate salt.

4. A composition comprising the peptide of claim 1 and a pharmaceutically acceptable carrier.

5. The composition of claim 4 , wherein the peptide is in the form of a chloride salt.

6. The composition of claim 4 , wherein the peptide is in the form of an acetate salt.

7. The composition of claim 4 , further comprising an adjuvant selected from the group consisting of anti-CD40 antibody, imiquimod, resiquimod, GM-CSF, cyclophosphamide, sunitinib, bevacizumab, interferon-alpha, interferon-beta, CpG oligonucleotides, poly-(I:C), RNA, sildenafil, particulate formulations with poly(lactide co-glycolide) (PLG), virosomes, interleukin (IL)-1, IL-2, IL-4, IL-7, IL-12, IL-13, IL-15, IL-21, and IL-23.

8. The composition of claim 7 , wherein the adjuvant is IL-2.

9. The composition of claim 7 , wherein the adjuvant is IL-7.

10. The composition of claim 7 , wherein the adjuvant is IL-12.

11. The composition of claim 7 , wherein the adjuvant is IL-15.

12. The composition of claim 7 , wherein the adjuvant is IL-21.

13. A composition comprising the peptide of claim 1 , wherein the composition is a pharmaceutical composition and comprises water and a buffer.

14. The composition of claim 7 , wherein the adjuvant is IL-1.

15. The composition of claim 7 , wherein the adjuvant is IL-4.

16. The composition of claim 7 , wherein the adjuvant is IL-13.

17. The composition of claim 7 , wherein the adjuvant is IL-23.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 27, 2021
From: WEINSCHENK, TONI; SCHOOR, OLIVER; TRAUTWEIN, CLAUDIA; HILF, NORBERT; WALTER, STEFFEN; SINGH, HARPREET
To: IMMATICS BIOTECHNOLOGIES GMBH
Reel/Frame 056049/0485 →
Priority Claims (3)
EP 08017305 · Oct 1, 2008 · regional
EP 08017921 · Oct 13, 2008 · regional
WO PCT/EP2009/006980 · Sep 28, 2009 · international
Continuity (6)
Continuation 16136008 · Sep 19, 2018
Continuation 14562156 · Dec 5, 2014
Division 13346598 · Jan 9, 2012
Division 12571776 · Oct 1, 2009
Provisional Application 61105928 · Oct 16, 2008
Related Publication 20210238227A1 · Aug 5, 2021
References Cited (93)
US 6589642B1 · Miller et al. · 2003 [cited by applicant]
US 6992176B2 · Reiter et al. · 2006 [cited by applicant]
US 7919467B2 · Ramakrishna et al. · 2011 [cited by applicant]
US 8008431B2 · Weinschenk et al. · 2011 [cited by applicant]
US 8119139B2 · Weinschenk et al. · 2012 [cited by applicant]
US 8318677B2 · Weinschenk et al. · 2012 [cited by applicant]
US 8653035B2 · Weinschenk et al. · 2014 [cited by applicant]
US 8669063B2 · Weinschenk et al. · 2014 [cited by applicant]
US 8747855B2 · Reiter et al. · 2014 [cited by applicant]
US 8961985B2 · Weinschenk et al. · 2015 [cited by applicant]
US 9283267B2 · Lewandrowski et al. · 2016 [cited by applicant]
US 9289478B2 · Lewandrowski et al. · 2016 [cited by applicant]
US 9901629B2 · Sonntag et al. · 2018 [cited by applicant]
US 10035838B2 · Sonntag et al. · 2018 [cited by applicant]
US 10364281B2 · Sonntag et al. · 2019 [cited by applicant]
US 10385110B2 · Sonntag et al. · 2019 [cited by applicant]
US 10385111B2 · Sonntag et al. · 2019 [cited by applicant]
US 10435454B2 · Sonntag et al. · 2019 [cited by applicant]
US 10464991B2 · Sonntag et al. · 2019 [cited by applicant]
US 10640547B2 · Sonntag et al. · 2020 [cited by applicant]
US 20020090672A1 · Rosen et al. · 2002 [cited by applicant]
US 20030175733A1 · Kirst et al. · 2003 [cited by applicant]
US 20050261166A1 · Wang et al. · 2005 [cited by applicant]
US 20060241166A1 · Magda · 2006 [cited by applicant]
US 20080207497A1 · Ramakrishna et al. · 2008 [cited by applicant]
US 20100021441A1 · Weinschenk et al. · 2010 [cited by applicant]
US 20100029573A1 · Weinschenk et al. · 2010 [cited by applicant]
US 20110142919A1 · Ramakrishna et al. · 2011 [cited by applicant]
US 20130045191A1 · Weinschenk et al. · 2013 [cited by applicant]
US 20140234347A1 · Weinschenk et al. · 2014 [cited by applicant]
US 20150125478A1 · Weinschenk et al. · 2015 [cited by applicant]
US 20170305991A1 · Sonntag et al. · 2017 [cited by applicant]
US 20170326216A1 · Sonntag et al. · 2017 [cited by applicant]
US 20180193439A1 · Sonntag et al. · 2018 [cited by applicant]
US 20190040112A1 · Sonntag et al. · 2019 [cited by applicant]
US 20190040113A1 · Sonntag et al. · 2019 [cited by applicant]
US 20190040114A1 · Sonntag et al. · 2019 [cited by applicant]
US 20190040115A1 · Sonntag et al. · 2019 [cited by applicant]
US 20190062401A1 · Sonntag et al. · 2019 [cited by applicant]
US 20190201443A1 · Joglekar et al. · 2019 [cited by applicant]
US 20190389930A1 · Sonntag et al. · 2019 [cited by applicant]
CN 109069587A · 2018 [cited by applicant]
EP 0570188A2 · 1993 [cited by applicant]
EP 1835027A1 · 2007 [cited by applicant]
EP 2111867A1 · 2009 [cited by applicant]
KR 101184869B1 · 2012 [cited by applicant]
WO 9831797A1 · 1998 [cited by applicant]
WO 200155368A1 · 2001 [cited by applicant]
WO 2002020036A1 · 2002 [cited by applicant]
WO 2002046767A2 · 2002 [cited by applicant]
WO 2002074237A2 · 2002 [cited by applicant]
WO 2003045998A2 · 2003 [cited by applicant]
WO 2004015390A2 · 2004 [cited by applicant]
WO 2005116051A2 · 2005 [cited by applicant]
WO 2007072505A2 · 2007 [cited by applicant]
WO 2007150077A2 · 2007 [cited by applicant]
WO 2008109757A2 · 2008 [cited by applicant]
WO 2010037514A2 · 2010 [cited by applicant]
WO 2017182395A1 · 2017 [cited by applicant]
Berge et al. (J. Pharm. Sci. Jan. 1977; 66 (1): 1-19). [cited by examiner]
Paulekuhn et al. (J. Med. Chem. Dec. 27, 2007; 50 (26): 6665-72). [cited by examiner]
Nakagawa et al. (Biophys J. Apr. 1, 2007; 92 (7): 2570-82). [cited by examiner]
Udaka et al. (Immunogenetics. Aug. 2000; 51 (10): 816-28). [cited by examiner]
Ljunggren et al. (Nature. Aug. 2, 1990; 346 (6283): 476-80). [cited by examiner]
Bilich et al. (Blood. Feb. 7, 2019; 133 (6): 550-565). [cited by examiner]
Stevens et al. (Eur. J. Immunol. Apr. 1998; 28 (4): 1272-9). [cited by examiner]
Hervé et al. (Mol. Immunol. Feb. 1997; 34 (2): 157-63). [cited by examiner]
He et al. (Life Sci. 1999; 65 (4): 355-68). [cited by examiner]
UNIPROT Accession No. A2T6A1; sequence version 1 (Feb. 6, 2007). [cited by applicant]
UNIPROT Accession No. A1YGC8; sequence version 1 (Feb. 6, 2007). [cited by applicant]
Extended European Search Report, EP 08 01 7921, Dec. 14, 2009. [cited by applicant]
Gunther et al., “Glioblastoma-derived stem cell-enriched cultures from distinct subgroups according to molecular and phenotypic criteria,” Oncogen (2008) 27, 00. 2897-2909 (XP-002557755). [cited by applicant]
Suzuki et al., “Genetic analysis of human glioblastomas using a genomic microarray system,” Brain Tumore Pathol (2004) 21, pp. 27-34 (XP-002557756). [cited by applicant]
Shibahara et al., “Podoplanin is expressed in subsets of tumors of the central nervous system,” Virchows Arch (2006) 448, pp. 493-499 (XP-002557757). [cited by applicant]
International Journal of Cancer, Journal of International DU Cancer, May 18, 1998, vol. 77: 04, pp. 451-458. [cited by applicant]
Gary et al., “cDNS Cloning, chromosomal localization, and expression analysis of human BEHAB/brevican, a brain specification proteoglycan regulated during cortical development and in glioma,” Gene, Elsevier, Amsterdam, … [cited by applicant]
International Preliminary Report on Patentability dated Apr. 5, 2011 from PCT/EP2009/006980 and Written Opinion, dated Apr. 1, 2011. [cited by applicant]
International Search Report dated Mar. 30, 2010 from PCT/EP2009/006980. [cited by applicant]
International Search Report dated Sep. 26, 2008 from PCT/EP2009/006980. [cited by applicant]
Meydan et al. (BMC Bioinformatics. 2013; 14 (Suppl. 2): S13; pp. 1-12). [cited by applicant]
Neefjes et al. (Nature Reviews Immunology. Dec. 2011; 11, 823-836). [cited by applicant]
Walter et al. (J. Immunol. Nov. 15, 2003; 171 (10): 4974-78). [cited by applicant]
Chen et al. (Arthritis Rheumatol. Feb. 2014; 66 (2): 284-94). [cited by applicant]
Li et al. (Front. Immunol. Nov. 22, 2013; 4: 383; pp. 1-8). [cited by applicant]
Obermann et al. (Immunology Sep. 2007; 122 (1): 90-97). [cited by applicant]
Mizukami et al. (Cancer Sci. Jul. 2008. 99(7): 1448-54). [cited by applicant]
Suda et al. (Cancer Sci. Nov. 2007; 98(1): 1803-08). [cited by applicant]
Delamarre et al. (Science. Mar. 11, 2005; 307 (5715): 1630-34). [cited by applicant]
Urban et al. (Proc. Natl. Acad. Sci. USA. Feb. 15, 1994; 91(4): 1534-38). [cited by applicant]
Chang et al. (Proc. Natl. Acad. Sci. USA. Nov. 22, 2005; 102(47): 17107-12). [cited by applicant]
Pascolo et al. (J. Exp. Med. Jun. 16, 1997; 185 (12); 2043-51). [cited by applicant]
Andresen, et al., “Linaclotide acetate.” Drugs of the Future 33, No. 7 (2008). [cited by applicant]
Sikora, et al., “The role of counter-ions in peptides—an overview.” Pharmaceuticals 13, No. 12 (2020): 442. [cited by applicant]